Status:
UNKNOWN
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
Lead Sponsor:
Aswan University
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.
Eligibility Criteria
Inclusion
- with non-valvular paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset).
- Patient age 18-60 years.
- Patients with Glomerular Filtration Rate (GFR) \>45 ml/min/1.73m2 (Cockcroft-Gault equation).
- Patient with normal left atrium or dilated (diameter \<5 cm)
Exclusion
- Patients \< 18 yrs old.
- Patients with valvular heart diseases (Moderate to severe MS, severe AS, Prosthetic heart valves).
- Patients with left atrium \> 5cm.
- Patients with glomerular Filtration Rate (GFR) \<45 ml/min/1.73m2 (Cockcroft-Gault equation).
- Patient with ischemic heart disease (previous MI, UA, PCI or CABG).
- Patient with previous ischemic stroke.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05993897
Start Date
August 1 2023
End Date
December 1 2024
Last Update
August 15 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.